LBP-MARCO + Ruxolitinib for Graft-versus-Host Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
The researchers are doing this study to find out whether the combination of LBP-MARCO (Microbiota Augmentation to Reestablish Commensal Organisms) and ruxolitinib is a safe treatment for people with graft-versus-host disease (GVHD) after receiving a stem cell (allogeneic hematopoietic cell transplantation).
Who Is on the Research Team?
Doris Ponce, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for people who have developed graft-versus-host disease (GVHD) after receiving a stem cell transplant from another person. Participants must meet certain health requirements and cannot join if they have conditions that would make participation unsafe.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- LBP-MARCO
- Ruxolitinib
Trial Overview
The study is testing whether combining LBP-MARCO, which aims to restore healthy gut bacteria, with the drug ruxolitinib is safe for treating GVHD. All participants will receive both treatments.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
If that combination does not grow in participants' guts, the next group of participants (Cohort 3) will get LBP-MARCO with a different combination of the bacteria.
If the bacteria do not grow or produce enough metabolites, the next group of participants (Cohort 2) will get LBP-MARCO with a different combination of bacteria.
Participants in Cohort 1 will receive LBP-MARCO with the same combination of 7 specific types of bacteria.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
University of Chicago
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.